Elevance Health (ELV) to Release Quarterly Earnings on Wednesday

Elevance Health (NYSE:ELV – Get Rating) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, January 25th. Analysts expect the company to announce earnings of $5.21 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Elevance Health Stock Performance

Shares of NYSE ELV traded up $0.58 during midday trading on Tuesday, hitting $478.52. 1,253,627 shares of the company’s stock were exchanged, compared to its average volume of 1,248,215. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.35 and a quick ratio of 1.35. The stock’s 50 day moving average price is $502.07 and its 200-day moving average price is $492.16. The firm has a market cap of $114.85 billion, a P/E ratio of 18.77, a PEG ratio of 1.22 and a beta of 0.89. Elevance Health has a twelve month low of $420.73 and a twelve month high of $549.52.

Institutional Trading of Elevance Health

Several large investors have recently added to or reduced their stakes in the company. EP Wealth Advisors LLC acquired a new stake in Elevance Health during the 1st quarter valued at $783,000. Capital World Investors acquired a new stake in Elevance Health during the 1st quarter valued at $190,648,000. Gabelli Funds LLC raised its stake in Elevance Health by 1.5% during the 1st quarter. Gabelli Funds LLC now owns 34,500 shares of the company’s stock valued at $16,947,000 after purchasing an additional 500 shares during the period. Wealthfront Advisers LLC raised its stake in Elevance Health by 38.3% during the 1st quarter. Wealthfront Advisers LLC now owns 19,268 shares of the company’s stock valued at $9,465,000 after purchasing an additional 5,340 shares during the period. Finally, Weiss Multi Strategy Advisers LLC acquired a new stake in Elevance Health during the 1st quarter valued at $1,228,000. 87.66% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ELV has been the subject of several analyst reports. Morgan Stanley boosted their price objective on Elevance Health from $485.00 to $500.00 and gave the stock an “equal weight” rating in a research report on Friday, October 21st. StockNews.com initiated coverage on Elevance Health in a research report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Deutsche Bank Aktiengesellschaft boosted their target price on Elevance Health from $576.00 to $581.00 and gave the stock a “buy” rating in a report on Friday, October 21st. Wells Fargo & Company boosted their target price on Elevance Health from $557.00 to $609.00 and gave the stock an “overweight” rating in a report on Wednesday, January 4th. Finally, UBS Group boosted their target price on Elevance Health from $585.00 to $610.00 in a report on Monday, October 24th. One investment analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Elevance Health currently has an average rating of “Buy” and an average target price of $578.89.

Elevance Health Company Profile

(Get Rating)

Elevance Health, Inc operates as a health company, which engages in improving lives and communities, and making healthcare simpler. The firm supports consumers, families, and communities across the entire care journey, connecting them to the care, support, and resources they need to lead healthier lives.